长春瑞滨联合卡培他滨治疗28例转移性乳腺癌

目的：观察长春瑞滨联合卡培他滨治疗转移性乳腺癌的疗效及安全性。方法：28例有可测量病灶的转移性乳腺癌患者，中心静脉持续滴注(Civ)长春瑞滨：6mg／m^2，第1—5天，21天为一个周期，同时联合卡培他滨治疗2—4个周期。所有患者既往均接受过1种以上化疗方案的治疗，其中19例接受过蒽环类和(或)紫杉类治疗。结果：28例患者中13例接受了2个周期化疗，15例完成4个周期的化疗。CR 1例(3．57％)，PR 6例(21．43％)，MR7例(25．0％)，SD7例(25．0％)，PD7例(25．0％)，有效率达50．0％。最常见的不良反应为中性粒细胞减少、手足综合症、神经毒性、皮肤色素沉着、乏力等。结论：长春瑞滨联合卡培他滨作为二线方案治疗转移性乳腺癌的疗效确切，且不良反应可以耐受。有望成为转移性乳腺痛的理想二线化疗方案。

Vinorelbine combined with capecitabine in the treatment of advanced and metastatic breast cancer

Purpose:To study the efficiency and safety on vinorelbine combined with capecitabine in the treatment of metastatic breast cancer. Methods:Twenty-eight patients with measurable lesions of metestetic breast cancer received vinorelbine 6 mg/m 2 d 1-5 civ,cycles were repeated every 21 days. Patients received capecitabine for 2-4 cycles at the same time. All patients received more than one course of chemotherapy regimens and 19 patients had adriamycin and (or) paclitaxel treatment. Results:Thirteen patients received two cycles treatment and fifteen patients received four cycles of treatment. Complete response in one patient,partial response in six patients,minor response in seven patients,stable response in seven patients and progressive disease in seven patients were observed. Overall responsed rate was 50%.The common side effects were neutronpenia,hand-foot syndrome,skin pigmentation,fatigue. Conclusions:The combination of vinorelbine and capecitabine in the treatment of metastatic breast cancer was effective and the toxicities were tolerable. It is possible that this regimen is an ideal second line chemotherapy for metastatic breast cancer.